NO20062967L - Mutert virus, fremgangsmate for fremstilling, og anvendelse av samme - Google Patents

Mutert virus, fremgangsmate for fremstilling, og anvendelse av samme

Info

Publication number
NO20062967L
NO20062967L NO20062967A NO20062967A NO20062967L NO 20062967 L NO20062967 L NO 20062967L NO 20062967 A NO20062967 A NO 20062967A NO 20062967 A NO20062967 A NO 20062967A NO 20062967 L NO20062967 L NO 20062967L
Authority
NO
Norway
Prior art keywords
virion
pneumoviral
infectivity
virions
protein
Prior art date
Application number
NO20062967A
Other languages
English (en)
Other versions
NO334756B1 (no
Inventor
Willem Luytjes
Myra Noorely Widjojoatmodjo
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of NO20062967L publication Critical patent/NO20062967L/no
Publication of NO334756B1 publication Critical patent/NO334756B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18532—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material
    • C12N2760/18552—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelsen vedrører pneumovirale virioner omfattende et viralt genom som har en mutasjon i et gen som koder for et protein som er essensielt for infektivitet av pneumovi ruset, hvor ved mutasjonen fører til at et virus som fremstilles bare fra det virale genomet mangler infektivitet, og hvor virionet omfatter proteinet i en form og mengde som kreves for infektivitet av virionet. Oppfinnelsen vedrører fremgangsmåter for å produsere de pneumovirale virionene og for anvendelse av virionene i behandling eller forebygging av pneumoviral infeksjon og sykdom. Et foretrukket pneumoviralt virion er et virion til Respiratorisk Syncytial Virus hvori fortrinnsvis genet for G tilknytningsproteinet er inaktivert og komplimentert in trans.
NO20062967A 2003-12-24 2006-06-26 Virion fra humant Respiratorisk Syncytial Virus, sammensetninger omfattende nevnte virus, fremgangsmåte for fremstilling derav, og anvendelser derav. NO334756B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300930 2003-12-24
PCT/NL2004/000911 WO2005061698A1 (en) 2003-12-24 2004-12-24 A respiratory syncytial virus with a genomic deficiency complemented in trans

Publications (2)

Publication Number Publication Date
NO20062967L true NO20062967L (no) 2006-09-22
NO334756B1 NO334756B1 (no) 2014-05-19

Family

ID=34709376

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062967A NO334756B1 (no) 2003-12-24 2006-06-26 Virion fra humant Respiratorisk Syncytial Virus, sammensetninger omfattende nevnte virus, fremgangsmåte for fremstilling derav, og anvendelser derav.

Country Status (24)

Country Link
US (3) US9107939B2 (no)
EP (2) EP1699919B1 (no)
JP (1) JP4814799B2 (no)
KR (1) KR101266715B1 (no)
CN (1) CN1922309B (no)
AU (1) AU2004303719B2 (no)
BR (1) BRPI0418093A (no)
CA (1) CA2551009C (no)
CY (1) CY1118741T1 (no)
DK (1) DK1699919T3 (no)
EA (1) EA011878B1 (no)
ES (2) ES2618523T3 (no)
HK (1) HK1100494A1 (no)
HU (1) HUE032898T2 (no)
IL (1) IL176500A (no)
LT (1) LT1699919T (no)
NO (1) NO334756B1 (no)
NZ (1) NZ548107A (no)
PL (1) PL1699919T3 (no)
PT (1) PT1699919T (no)
SI (1) SI1699919T1 (no)
TR (1) TR201808496T4 (no)
WO (1) WO2005061698A1 (no)
ZA (1) ZA200605218B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121210D0 (en) * 2011-12-09 2012-01-18 Health Prot Agency Respiratory infection assay
JP6253161B2 (ja) 2012-03-05 2017-12-27 デ スタート デル ネーデルランデン， ヴェルト． ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト， ベルジーン エン シュポルトＤｅ Ｓｔａａｔ Ｄｅｒ Ｎｅｄｅｒｌａｎｄｅｎ， Ｖｅｒｔ． Ｄｏｏｒ Ｄｅ Ｍｉｎｉｓｔｅｒ Ｖａｎ Ｖｗｓ Ｍｉｎｉｓｔｅｒｉｅ Ｖａｎ Ｖｏｌｋｓｇｅｚｏｎｄｈｅｉｄ， Ｗｅｌｚｉｊｎ Ｅｎ Ｓｐｏｒｔ 乾燥された生物学的材料を安定化するための方法及び組成物
US10232032B2 (en) 2013-03-14 2019-03-19 Emory University Recombinant RSV with silent mutations, vaccines, and methods related thereto
SI3010537T1 (sl) 2013-06-17 2018-09-28 De Staat der Nederlanden, Vert. Door de Minister Van Vws Ministerie Van Volksgezondheid Welzijn en Sport Metode za preprečevanje agregacije virusnih komponent
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
BR112018008708A2 (pt) 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
CN112746059A (zh) * 2020-09-15 2021-05-04 清华大学 基于病毒结构蛋白遗传互补的冠状病毒细胞模型
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN114990079B (zh) * 2022-04-29 2023-07-04 广州医科大学附属第一医院（广州呼吸中心） 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
CA2230033C (en) * 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
EP1035205A1 (en) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US6921535B2 (en) * 2000-06-23 2005-07-26 Akzo Nobel N.V. Attenuated Bovine Respiratory Syncytial virus
WO2003029416A2 (en) * 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof

Also Published As

Publication number Publication date
DK1699919T3 (en) 2017-03-20
EA011878B1 (ru) 2009-06-30
KR20070022210A (ko) 2007-02-26
JP4814799B2 (ja) 2011-11-16
KR101266715B1 (ko) 2013-05-28
PT1699919T (pt) 2017-04-03
US9107939B2 (en) 2015-08-18
EA200601218A1 (ru) 2006-12-29
HUE032898T2 (hu) 2017-11-28
NZ548107A (en) 2009-09-25
US20100291035A1 (en) 2010-11-18
ES2670713T3 (es) 2018-05-31
US20150329833A1 (en) 2015-11-19
US9889168B2 (en) 2018-02-13
BRPI0418093A (pt) 2007-04-17
NO334756B1 (no) 2014-05-19
ES2618523T3 (es) 2017-06-21
ZA200605218B (en) 2007-05-30
AU2004303719B2 (en) 2010-11-11
JP2007516721A (ja) 2007-06-28
WO2005061698A1 (en) 2005-07-07
TR201808496T4 (tr) 2018-07-23
EP1699919B1 (en) 2017-01-11
US20180207211A1 (en) 2018-07-26
EP1699919A1 (en) 2006-09-13
IL176500A0 (en) 2006-10-05
AU2004303719A1 (en) 2005-07-07
EP2500419A1 (en) 2012-09-19
CA2551009A1 (en) 2005-07-07
SI1699919T1 (sl) 2017-07-31
HK1100494A1 (en) 2007-09-21
PL1699919T3 (pl) 2017-08-31
CN1922309A (zh) 2007-02-28
IL176500A (en) 2015-02-26
CN1922309B (zh) 2011-07-13
CA2551009C (en) 2017-01-17
LT1699919T (lt) 2017-04-25
CY1118741T1 (el) 2017-07-12
EP2500419B1 (en) 2018-03-21
US10967014B2 (en) 2021-04-06

Similar Documents

Publication Publication Date Title
NO20062967L (no) Mutert virus, fremgangsmate for fremstilling, og anvendelse av samme
Isakova-Sivak et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2)
White et al. Medical virology
Kofler et al. Functional analysis of the tick-borne encephalitis virus cyclization ElementsIndicates major differences between mosquito-borne and tick-borne flaviviruses
HU229101B1 (en) Dna transfection system for the generation of infectious influenza virus
BRPI0416187A (pt) método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i
EP1736539A1 (en) Attenuated SARS-CoV vaccines
US10662464B2 (en) Methods of analyzing virus-derived therapeutics
Novella Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution
Le Nouën et al. Optimization of the codon pair usage of human respiratory syncytial virus paradoxically resulted in reduced viral replication in vivo and reduced immunogenicity
DK1802746T3 (da) Virosompartikler indeholdende antigener fra influenzavirus og hepatitis B-virus
Ye et al. Error-prone pcr-based mutagenesis strategy for rapidly generating high-yield influenza vaccine candidates
Gutiérrez et al. Biased mutational pattern and quasispecies hypothesis in H5N1 virus
Novella et al. Adaptability costs in immune escape variants of vesicular stomatitis virus
Janowski et al. The highly conserved stem-loop II motif is important for the lifecycle of astroviruses but dispensable for SARS-CoV-2
Smit et al. Measles virus genotype B2 is not inactive: evidence of continued circulation in Africa
CN1478147A (zh) 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
Fulton Defining the mutational tolerance of the antigenic domains of influenza, measles, and Zika viruses
Penrice-Randal Understanding severe coronavirus disease in humans from the analysis of clinical samples with RNA sequencing
Lee Viral polymerase mechanism-based strategies for viral attenuation and vaccine development
Lázaro Genetic Variability in RNA Viruses: Consequences in Epidemiology and in the Development of New Stratgies for the Extinction of Infectivity
Bordería et al. Reverse genetics and quasispecies

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: INTRAVACC B.V., NL

MM1K Lapsed by not paying the annual fees